HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats.

Abstract
Several bariatric operations are currently used to treat obesity and obesity-related comorbidities. These vary in efficacy, but most are more effective than current pharmaceutical treatments. Roux-en-Y gastric bypass (RYGB) produces substantial body weight (BW) loss and enhanced glucose tolerance, and is associated with increased secretion of the gut hormone glucagon-like peptide 1 (GLP-1). Given the success of GLP-1-based agents in lowering blood glucose levels and BW, we hypothesized that an individual sensitivity to GLP-1 receptor agonism could predict metabolic benefits of surgeries associated with increased GLP-1 secretion. One hundred ninety-seven high-fat diet-induced obese male Long-Evans rats were monitored for BW loss during exendin-4 (Ex4) administration. Stable populations of responders and nonresponders were identified based on Ex4-induced BW loss and GLP-1-induced improvements in glucose tolerance. Subpopulations of Ex4 extreme responders and nonresponders underwent RYGB surgery. After RYGB, responders and nonresponders showed similar BW loss compared with sham, but nonresponders retained impaired glucose tolerance. These data indicate that the GLP-1 response tests may predict some but not all of the improvements observed after RYGB. These findings present an opportunity to optimize the use of bariatric surgery based on an improved understanding of GLP-1 biology and suggest an opportunity for a more personalized therapeutic approach to the metabolic syndrome.
AuthorsKirk M Habegger, Kristy M Heppner, Sarah E Amburgy, Nickki Ottaway, Jenna Holland, Christine Raver, Erin Bartley, Timo D Müller, Paul T Pfluger, Jose Berger, Mouhamadoul Toure, Stephen C Benoit, Richard D Dimarchi, Diego Perez-Tilve, David A D'Alessio, Randy J Seeley, Matthias H Tschöp
JournalDiabetes (Diabetes) Vol. 63 Issue 2 Pg. 505-13 (Feb 2014) ISSN: 1939-327X [Electronic] United States
PMID24186863 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Dietary Fats
  • Glp1r protein, rat
  • Glucagon-Like Peptide-1 Receptor
  • Peptides
  • Receptors, Glucagon
  • Venoms
  • Exenatide
Topics
  • Animals
  • Dietary Fats (adverse effects)
  • Eating
  • Exenatide
  • Gastric Bypass
  • Gene Expression Regulation (physiology)
  • Glucagon-Like Peptide-1 Receptor
  • Glucose Tolerance Test
  • Male
  • Obesity
  • Peptides (pharmacology)
  • Rats
  • Rats, Long-Evans
  • Receptors, Glucagon (agonists, genetics, metabolism)
  • Venoms (pharmacology)
  • Weight Loss

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: